查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1654386

帕金森氏症治療市場規模、佔有率、趨勢分析報告：按藥物類別、分銷管道、地區、細分預測，2025-2030 年

Parkinson's Disease Treatment Market Size, Share & Trends Analysis Report By Drug Class, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

帕金森氏症治療市場的成長和趨勢

根據Grand View Research, Inc.的最新報告，全球帕金森氏症治療市場預計到2030年將達到75.8億美元，2025年至2030年期間的複合年成長率為5.04%。這是由於對 PD 新治療方法研發的投入不斷增加。 2021 年 8 月，帕金森基金會宣布將向 29 個研究計劃投資 4,300 萬美元的研究津貼，旨在開發帕金森氏症的新治療方法和治療方法。此外，2021 年 5 月，帕金森基金會宣布將投資 1,000 萬美元用於帕金森氏症 (PD) 相關的研究、護理和教育計畫。這項投資將有助於為患有 PD 的人提供免費的認知和基因測試。

預計此類投資舉措將促進工業成長。過去十年，帕金森氏症治療領域出現了大量研發活動，推動了創新藥物傳遞方法的發展。這些先進的藥物傳輸系統比現有的系統效果更佳，因為它們的副作用更少。此外，患者依從性的提高導致這些技術的複合率增加，從而推動了該行業的擴張。此外，各大製藥公司正在進行合作研究和合作開發、生產和商業化產品，以滿足國際市場對疾病治療日益成長的需求。

例如，2021 年 11 月，STADA Arzneimittel 與 Bioglan 達成夥伴關係，以擴大用於治療 PD 患者的藥物 Lecigon（左旋多巴/碳度巴/entacapone）的生產能力。因此，用於治療 PD 患者的藥物的需求不斷增加預計將推動該行業的成長。然而，神經科醫生數量有限造成了患者等候時間長以及醫院招募新神經外科醫生困難等問題。此外，一些目前執業的神經科不願意接受新的醫療補助患者，這給想要轉換醫生的患者帶來了困難。根據美國神經病學會 (AAN) 的報告，到 2025 年，神經病學家的短缺人數預計將達到約 19%。

帕金森氏症治療市場報告重點

  • Carbidopa-Levodopa製劑在帕金森氏症治療市場佔據主導地位，2024 年佔據 25.12% 的最大銷售佔有率，這得益於其對震顫、僵硬和心搏過緩等​​症狀的長期療效。
  • 預計零售藥局部門將在 2024 年佔據帕金森氏症治療市場的主導地位，收益佔有率為 41.59%，並且由於其廣泛的可用性和對患者的便利性，預計在預測期內將以最快的速度成長。
  • 由於患病率高、醫療基礎設施先進以及研發投入龐大等多種因素，北美在帕金森氏症治療市場佔據主導地位，2024 年的收入佔有率為 38.03%。
  • 受醫療支出增加、人口老化以及消費者對神經系統健康意識增強的推動，亞太地區帕金森氏症治療產業正在快速成長。

目錄

第1章調查方法與範圍

第 2 章執行摘要

3. 帕金森氏症治療市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 帕金森氏症治療市場分析工具
    • 產業分析 – 波特五力分析
    • PESTEL 分析

第 4 章帕金森氏症治療市場：按藥物類別的估計和趨勢分析

  • 細分儀表板
  • 帕金森氏症治療市場：藥物類別變化分析
  • 帕金森氏症治療市場（按藥物類別分類）
  • 2018-2030 年市場規模、預測及趨勢分析
  • Carbidopa-Levodopa
  • 促效劑
  • MAO-B 抑制劑
  • COMT 抑制劑
  • 抗膽鹼能藥物
  • 其他

第 5 章帕金森氏症治療市場：按分銷管道進行的估計和趨勢分析

  • 細分儀表板
  • 帕金森氏症治療市場：分銷管道變化分析
  • 帕金森氏症治療市場前景（按分銷管道分類）
  • 2018-2030 年市場規模、預測及趨勢分析
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第6章：帕金森氏症治療市場：區域、估計和趨勢分析

  • 區域控制面板
  • 2018-2030 年市場規模及預測趨勢分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭格局

  • 市場參與企業分類
  • 主要市場參與企業的近期趨勢和影響分析
  • 2024 年公司市場佔有率分析
  • 主要企業簡介
    • Cerevel Therapeutics
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • Merck &Co., Inc.
    • GlaxoSmithKline plc.（GSK）
    • AbbVie, Inc.
    • H. Lundbeck A/S
    • Amneal Pharmaceuticals LLC
    • Supernus Pharmaceuticals, Inc.
Product Code: GVR-4-68039-990-7

Parkinson's Disease Treatment Market Growth & Trends:

The global parkinson's disease treatment market size is expected to reach USD 7.58 billion by 2030, registering a CAGR of 5.04% from 2025 to 2030, according to a new report by Grand View Research, Inc. This can be attributed to the rising investment in the research and development of novel treatments for PD. In August 2021, the Parkinson's Foundation announced an investment of USD 43 million as a research grant to 29 research projects having the goal of developing novel treatments and therapies for PD. In addition, in May 2021, the Parkinson's Foundation announced an investment of USD 10 million for research, care, and educational programs related to Parkinson's Disease (PD). This investment may aid in providing awareness and genetic testing free of cost to people suffering from PD.

Such investment initiatives are expected to boost industry growth. In the last ten years, there have been significant R&D activities in the PD therapy sector, leading to the development of innovative drug-delivery methods. Due to fewer side effects, these cutting-edge drug delivery systems outperform the existing ones. In addition, the rate of prescription for these techniques has increased due to a rise in patient compliance, which is fueling the expansion of the industry. Moreover, key pharmaceutical companies are undertaking initiatives, such as collaborations and partnerships, for the development, manufacturing & commercialization of products to meet the rising demand for disease treatment in the international market.

For instance, in November 2021, STADA Arzneimittel and Bioglan formed a partnership to expand the production capacity of the medicine Lecigon (levodopa/carbidopa/entacapone) used to treat patients with PD. Thus, increasing demand for medicines that are used to treat patients with PD is anticipated to drive industry growth. However, the limited availability of neurologists leads to issues, such as longer waiting times for patients and difficulty in hiring new neurosurgeons in hospitals. In addition, some of the currently practicing neurologists avoid accepting new Medicaid patients, which creates difficulty for patients who want to switch to another doctor. According to the American Academy of Neurology (AAN) report, around 19% shortage of neurologists is projected by 2025.

Parkinson's Disease Treatment Market Report Highlights:

  • The carbidopa-levodopa segment dominated the Parkinson's disease treatment industry and accounted for the largest revenue share of 25.12% in 2024 due to its long-established efficacy in managing symptoms, particularly tremors, stiffness, and bradykinesia.
  • The retail pharmacy segment dominated the Parkinson's disease treatment market with the revenue share of 41.59% in 2024 and is anticipated to witness the fastest growth over the forecast period due to its widespread accessibility and convenience for patients.
  • North America dominated the Parkinson's disease treatment market with a revenue share of 38.03% in 2024 due to a combination of factors such as a high prevalence of the disease, advanced healthcare infrastructure, and significant research and development investments.
  • The Asia Pacific Parkinson's disease treatment industry is experiencing rapid growth, attributed to rising healthcare expenditure, an aging population, and increased consumer awareness of neurological health.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug
    • 1.2.2. Distribution Channel
    • 1.2.3. Regional Scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Parkinson's Disease Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Advancements in treatment options
      • 3.2.1.2. Rising prevalence of Parkinson's disease
      • 3.2.1.3. Increased research and investment
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High treatment costs
      • 3.2.2.2. Regulatory and Reimbursement Challenges
  • 3.3. Parkinson's Disease Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Parkinson's Disease Treatment Market: Drug Class Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Parkinson's Disease Treatment Market: Drug Class Movement Analysis
  • 4.3. Parkinson's Disease Treatment Market by Drug Class (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Carbidopa-Levodopa
    • 4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Dopamine Agonists
    • 4.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. MAO-B Inhibitors
    • 4.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. COMT Inhibitors
    • 4.8.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Anticholinergics
    • 4.9.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.10. Others
    • 4.10.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Parkinson's Disease Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Parkinson's Disease Treatment Market: Distribution Channel Movement Analysis
  • 5.3. Parkinson's Disease Treatment Market by Distribution Channel Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 To 2030 for the following
  • 5.5. Hospital Pharmacy
    • 5.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Retail Pharmacy
    • 5.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Online Pharmacy
    • 5.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Parkinson's Disease Treatment Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Dashboard
  • 6.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.3. Mexico
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement structure
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Norway
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Argentina
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Market Participant Categorization
  • 7.2. Recent Developments & Impact Analysis by Key Market Participants
  • 7.3. Company Market Share Analysis, 2024
  • 7.4. Key Company Profiles
    • 7.4.1. Cerevel Therapeutics
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Novartis AG
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Teva Pharmaceutical Industries Ltd.
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Merck & Co., Inc.
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. GlaxoSmithKline plc. (GSK)
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. AbbVie, Inc.
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. H. Lundbeck A/S
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Amneal Pharmaceuticals LLC
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Supernus Pharmaceuticals, Inc.
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Regulatory Framework
  • Table 4 Global Parkinson's disease treatment market, By Region, 2018 - 2030 (USD Million)
  • Table 5 Global Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 6 Global Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 7 North America Parkinson's disease treatment market, By Country, 2018 - 2030 (USD Million)
  • Table 8 North America Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 9 North America Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 10 U.S. Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 11 U.S. Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 12 Canada Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 13 Canada Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 14 Mexico Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 15 Mexico Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 16 Europe Parkinson's disease treatment market, By Country, 2018 - 2030 (USD Million)
  • Table 17 Europe Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 18 Europe Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 19 UK Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 20 UK Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 21 Germany Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 22 Germany America Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 23 France Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 24 France Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 25 Spain Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 26 Spain Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 27 Italy Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 28 Italy Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 29 Denmark Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 30 Denmark Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 31 Sweden Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 32 Sweden Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 33 Norway Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 34 Norway Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific Parkinson's disease treatment market, By Country, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 37 Asia Pacific Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 38 China Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 39 China Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 40 Japan Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 41 Japan Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 42 India Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 43 India Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 South Korea Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 45 South Korea Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 46 Australia Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 47 Australia Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 48 Thailand Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 49 Thailand Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 50 Latin America Parkinson's disease treatment market, By Country, 2018 - 2030 (USD Million)
  • Table 51 Latin America Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 52 Latin America Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 53 Brazil Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 54 Brazil Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 55 Argentina Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 56 Argentina Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 57 MEA Parkinson's disease treatment market, By Country, 2018 - 2030 (USD Million)
  • Table 58 MEA Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 59 MEA Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 60 South Africa Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 61 South Africa Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 63 Saudi Arabia Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 64 UAE Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 65 UAE Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 66 Kuwait Parkinson's disease treatment market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 67 Kuwait Parkinson's disease treatment market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research approaches
  • Fig. 2 Value chain-based sizing & forecasting
  • Fig. 3 Market formulation & validation
  • Fig. 4 Parkinson's disease treatment market segmentation
  • Fig. 5 Market driver analysis (current & future impact)
  • Fig. 6 Market restraint analysis (current & future impact)
  • Fig. 7 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 8 Porter's five forces analysis
  • Fig. 9 Parkinson's disease treatment market: Drug class outlook and key takeaways
  • Fig. 10 Parkinson's disease treatment market: Drug class movement analysis
  • Fig. 11 Carbidopa-Levodopa market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 12 Dopamine Agonist market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 13 MAO-B Inhibitors market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 14 COMT inhibitors market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 15 Anticholinergics market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 16 Others market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 17 Parkinson's disease treatment market: Distribution channel outlook and key takeaways
  • Fig. 18 Parkinson's disease treatment market: Distribution channel movement analysis
  • Fig. 19 Hospital Pharmacy market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 20 Retail Pharmacy market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 21 Online Pharmacy market estimates and forecast, 2018-2030 (USD Million)
  • Fig. 22 North America Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 U.S. Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Canada Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Mexico Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Europe Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 UK. Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Germany Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 France Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Italy Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Spain Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Denmark Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Sweden Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Norway Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Asia Pacific Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Japan Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 China Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 India Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Australia Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Thailand Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 South Korea Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Latin America Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Brazil Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Argentina Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 MEA Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 South Africa Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Saudi Arabia Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 UAE Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Kuwait Parkinson's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 List of key emerging companies/disruptors/innovators